{
  "id": 17783695,
  "title": "Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials",
  "url": "https://urgent.news/2026/11/02/povorcitinib-for-nonsegmental-vitiligo-two-randomized-controlled",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-02T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04739-2"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 02 November 2026; doi:10.1038/s41591-026-04739-2 In the STOP-V1 and STOP-V2 trials, povorcitinib (an oral JAK1 inhibitor) was superior to placebo in improvement in F-VASI75 score in individuals with nonsegmental vitiligo.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}